216
Participants
Start Date
March 20, 2021
Primary Completion Date
February 25, 2022
Study Completion Date
February 25, 2022
Oxbryta® (voxelotor) 500-mg Tablets
Patients will have received treatment with Oxbryta as prescribed by their physician at the approved dose per local prescribing information, as part of their usual care.
Montefiore Medical Center, The Bronx
Duke University Medical Center, Durham
Levine Cancer Institute, Charlotte
Central Michigan University/Children's Hospital of Michigan, Detroit
Parkland Health & Hospital System, Dallas
UT Southwestern Medical Center, Dallas
University of Texas Health Science Center at Houston, Houston
University of Connecticut Health, Farmington
Brigham and Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston
Rutgers Robert Wood Johnson Medical School Pediatric Clinical Research Center, New Brunswick
Rutgers Cancer Institute of New Jersey, New Brunswick
Lead Sponsor
Pfizer
INDUSTRY